Asia Impact Award Winner

Powered by

In 2018, Dr Yijia Li joined Tsinghua University Yangtze Delta Research Institute and became the founder and director of stem cell drug translational research platform. With 50 employees and more than 100 collaborators, the company is developing stem cell therapy for Knee Osteoarthritis, Stroke, Chronic Kidney Disease and Crohn’s disease. The company hopes that within 5 years, their first drug will be approved and many patients will be cured.